Status of vaccine research and development of vaccines for GBS

Vaccine

Volumn 34, Issue 26, 2016, Pages 2876-2879

  Heath, Paul T ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Conjugate; Group B streptococcus; Pregnancy; Streptococcus agalactiae; Vaccine

Indexed keywords

STREPTOCOCCUS AGALACTIAE B VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG LEGISLATION; DRUG RESEARCH; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNOGENICITY; LOWEST INCOME GROUP; MIDDLE INCOME COUNTRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEROLOGY; SOCIOECONOMICS; VACCINATION; VACCINE PRODUCTION; FEMALE; MEDICAL RESEARCH; MENINGITIS; NEONATAL SEPSIS; NEWBORN; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TRENDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT, NEWBORN; MENINGITIS; NEONATAL SEPSIS; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE;

EID: 84962144009     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.072     Document Type: Article

References (38)

1. Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz L.B., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000, 342(1):15-20.
2. Gray K.J., Bennett S.L., French N., Phiri A.J., Graham S.M. Invasive group B streptococcal infection in infants: Malawi. Emerg Infect Dis 2007, 13(2):223-229.
3. Madhi S.A., Radebe K., Crewe-Brown H., Frasch C.E., Arakere G., Mokhachane M., et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 2003, 23(1):15-23.
4. Dagnew A.F., Cunnington M.C., Dube Q., Edwards M.S., French N., Heyderman R.S., et al. Variation in reported neonatal group B streptococcal disease incidence in developing countries. Clin Infect Dis 2012, 55(1):91-102.
5. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379(9815):547-556.
6. Jones N., Oliver K.A., Barry J., Harding R.M., Bisharat N., Spratt B.G., et al. Carriage of group B streptococcus in pregnant women from Oxford: UK. J Clin Pathol 2006, 59(4):363-366.
7. Bergeron M.G., Ke D., Ménard C., Picard F.J., Gagnon M., Bernier M., et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000, 343(3):175-179.
8. Heath P.T., Balfour G.F., Tighe H., Verlander N.Q., Lamagni T.L., Efstratiou A., et al. Group B streptococcal disease in infants: a case control study. Arch Dis Child 2009, 94(9):674-680.
9. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recomm Rep 1996, 45(RR-7):1-24.
10. Libster R., Edwards K.M., Levent F., Edwards M.S., Rench M.A., Castagnini L.A., et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012, 130(1):e8-e15.
11. Bedford H., de Louvois J., Halket S., Peckham C., Hurley R., Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001, 323(7312):533-536.
12. Kim S.Y., Russell L.B., Park J., Verani J.R., Madhi S.A., Cutland C.L., et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine 2014, 32(17):1954-1963.
13. Nan C., Dangor Z., Cutland C.L., Edwards M.S., Madhi S.A., Cunnington M.C. Maternal group B Streptococcus-related stillbirth: a systematic review. BJOG 2015, 122(11):1437-1445.
14. Lancefield R.C. Two serological types of group B hemolytic streptococci with related: but not identical, type-specific substances. J Exp Med 1938, 67(1):25-40.
15. Baker C.J., Rench M.A., Edwards M.S., Carpenter R.J., Hays B.M., Kasper D.L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New Engl J Med 1988, 319(November (18)):1180-1185.
16. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003, 188(1):66-73.
17. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21(July (24)):3468-3472.
18. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hickman M.E., et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999, 179(January (1)):142-150.
19. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Edwards M.S., Kasper D.L. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004, 189(6):1103-1112.
20. WHO Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012, 47(87):461-476.
21. Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., Donegan K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014, 384(9953):1521-1528.
22. Schrag S.J., Zell E.R., Lynfield R., Roome A., Arnold K.E., Craig A.S., et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002, 347(4):233-239.
23. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001, 37(5):S34-S36. discussion 37.
24. Roberts J.N., Gruber M.F. Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine 2015, 33(8):966-972.
25. Baker C.J., Kasper D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976, 294(14):753-756.
26. Dangor Z., Kwatra G., Izu A., Lala S.G., Madhi S.A. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines 2015, 14(January (1)):135-149.
27. Baker C.J., Carey V.J., Rench M.A., Edwards M.S., Hillier S.L., Kasper D.L., et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014, 209(March (5)):781-788.
28. Lin F.Y.C., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004, 190(September (5)):928-934.
29. Kasper D.L., Wessels M.R., Guttormsen H.K., Paoletti L.C., Edwards M.S., Baker C.J. Measurement of human antibodies to type III group B Streptococcus. Infect Immun 1999, 67(8):4303-4305.
30. Kwatra G., Adrian P.V., Shiri T., Buchmann E.J., Cutland C.L., Madhi S.A. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women. Clin Microbiol Infect 2015.
31. Madhi S.A., Dangor Z., Heath P.T., Schrag S., Izu A., Sobanjo-Ter Meulen A., et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 2013, 31(Suppl 4):D52-D57.
32. Heath P.T. An update on vaccination against group B streptococcus. Expert Rev Vaccines 2011, 10(5):685-694.
33. Paoletti L.C., Rench M.A., Kasper D.L., Molrine D., Ambrosino D., Baker C.J. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 2001, 69(11):6696-6701.
34. Edwards M.S., Lane H.J., Hillier S.L., Rench M.A., Baker C.J. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 2012, 30(28):4123-4126.
35. Larsson C., Stalhammar-Carlemalm M., Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine 1999, 17(5):454-458.
36. Larsson C., Lindroth M., Nordin P., Stålhammar-Carlemalm M., Lindahl G., Krantz I. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 2006, 91(6):F403-F408.
37. Margarit I., Rinaudo C.D., Galeotti C.L., Maione D., Ghezzo C., Buttazzoni E., et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009, 199(1):108-115.
38. Oster G., Edelsberg J., Hennegan K., Lewin C., Narasimhan V., Slobod K., et al. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?. Vaccine 2014, 32(37):4778-4785.